HIV
Conditions
Interventions
Experimental group:TDF/TAF+FTC/3TC+ABT
Sponsors
The Second Hospital of Nanjing
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) =18 years old, gender is not limited; 2) HIV-1 antibody confirmatory test is positive; 3) HIV-1 RNA = 500 copies/mL; 4) 2.5?ULN<ALT<10?ULN or 1.6?ULN<TBIL<5?ULN; 5) Before performing any steps related to this study, subjects should understand and sign the informed consent form and comply with the requirements of this study.
Exclusion criteria
Exclusion criteria: 1) Progressive stage of liver failure; 2) Any liver disease caused by vascular, metabolic, autoimmune or tumor; 3) Severe cardiovascular disease, cancer, acute severe infection, kidney injury, and other diseases that the investigators judged not to be included 4) Subjects who have reported drug resistance to the test drug; 5) Known to be resistant to the study drug or allergic to the active ingredients or any additives of the study drug; 6) Alcohol-dependent or other patients who may affect test compliance; 7) Women who are pregnant, breastfeeding or planning to become pregnant; 8) Participates in clinical trials of other drugs within 30 days before enrollment.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Transaminase elevation events; | — |
Secondary
| Measure | Time frame |
|---|---|
| Grade 3-4 Adverse Events;HIV-1 RNA;CD4+ T cells;CD4/CD value; | — |
Countries
China
Contacts
Public ContactHongXia Wei
The Second Hospital of Nanjing
Outcome results
None listed